{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:32:04Z","timestamp":1793140324574,"version":"4.5.0"},"reference-count":118,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["CD21\/00095"],"award-info":[{"award-number":["CD21\/00095"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["DTS24\/00035"],"award-info":[{"award-number":["DTS24\/00035"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI22\/01342"],"award-info":[{"award-number":["PI22\/01342"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI24\/02008"],"award-info":[{"award-number":["PI24\/02008"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI22\/01345"],"award-info":[{"award-number":["PI22\/01345"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["DTS22\/00010"],"award-info":[{"award-number":["DTS22\/00010"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI23\/00945"],"award-info":[{"award-number":["PI23\/00945"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015755","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Endocrinology & Metabolism"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.tem.2025.03.006","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T16:11:48Z","timestamp":1744301508000},"page":"1000-1013","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1506-806X","authenticated-orcid":false,"given":"Bryan A.","family":"Priego-Parra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9452-1661","authenticated-orcid":false,"given":"Roc\u00edo","family":"Gallego-Dur\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7624-9679","authenticated-orcid":false,"given":"Berenice M.","family":"Rom\u00e1n-Calleja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6568-7048","authenticated-orcid":false,"given":"Jos\u00e9 Antonio","family":"Velarde-Ruiz Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-8947","authenticated-orcid":false,"given":"Manuel","family":"Romero-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7736-4089","authenticated-orcid":false,"given":"Jordi","family":"Gracia-Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tem.2025.03.006_bb0005","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tem.2025.03.006_bb0010","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.tem.2025.03.006_bb0015","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0020","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jhep.2021.10.016","article-title":"Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease","volume":"76","author":"Guo","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0025","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2331460","article-title":"Breaking the barriers: the role of gut homeostasis in metabolic-associated steatotic liver disease (MASLD)","volume":"16","author":"Bened\u00e9-Ubieto","year":"2024","journal-title":"Gut Microbes"},{"key":"10.1016\/j.tem.2025.03.006_bb0030","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41588-023-01497-6","article-title":"Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease","volume":"55","author":"Chen","year":"2023","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tem.2025.03.006_bb0035","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.3390\/nu15224757","article-title":"The role of epigenetic control of mitochondrial (dys)function in MASLD onset and progression","volume":"15","author":"Caputo","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.tem.2025.03.006_bb0040","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/liv.15830","article-title":"Novel insights into metabolic-associated steatotic liver disease preclinical models","volume":"44","author":"Montero-Vallejo","year":"2024","journal-title":"Liver Int."},{"key":"10.1016\/j.tem.2025.03.006_bb0045","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1007\/s12325-021-01690-1","article-title":"Perspectives on precision medicine approaches to NAFLD diagnosis and management","volume":"38","author":"Lonardo","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.tem.2025.03.006_bb0050","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/omi.2022.0079","article-title":"Multi-omics and artificial intelligence-guided data integration in chronic liver disease: prospects and challenges for precision medicine","volume":"26","author":"Lin","year":"2022","journal-title":"OMICS"},{"key":"10.1016\/j.tem.2025.03.006_bb0055","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202149641","article-title":"The \u201cDomino effect\u201d in MASLD: the inflammatory cascade of steatohepatitis","volume":"54","author":"Mladeni\u0107","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.tem.2025.03.006_bb0060","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1152\/physrev.00015.2017","article-title":"Interorgan metabolic crosstalk in human insulin resistance","volume":"98","author":"Gancheva","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.tem.2025.03.006_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111846","article-title":"Diabetes as a risk factor for MASH progression","volume":"217","author":"Gancheva","year":"2024","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.tem.2025.03.006_bb0070","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41574-023-00898-1","article-title":"Inter-organ crosstalk during development and progression of type 2 diabetes mellitus","volume":"20","author":"Xourafa","year":"2024","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.tem.2025.03.006_bb0075","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7570\/jomes23054","article-title":"Mitochondrial quality control: its role in metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"32","author":"Shin","year":"2023","journal-title":"J. Obes. Metab. Syndr."},{"key":"10.1016\/j.tem.2025.03.006_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108391","article-title":"PPAR-\u03b3 signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets","volume":"245","author":"Chen","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.tem.2025.03.006_bb0085","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00018-018-2947-0","article-title":"Molecular pathways of nonalcoholic fatty liver disease development and progression","volume":"76","author":"Bessone","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.tem.2025.03.006_bb0090","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-020-00411-3","article-title":"Role of liver sinusoidal endothelial cells in liver diseases","volume":"18","author":"Gracia-Sancho","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0095","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cmet.2024.05.003","article-title":"Metabolic reprogramming in liver fibrosis","volume":"36","author":"Horn","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.tem.2025.03.006_bb0100","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13578-022-00856-w","article-title":"New insights into fibrosis from the ECM degradation perspective: the macrophage-MMP-ECM interaction","volume":"12","author":"Zhao","year":"2022","journal-title":"Cell Biosci."},{"key":"10.1016\/j.tem.2025.03.006_bb0105","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3390\/cancers16020259","article-title":"MASLD and the development of HCC: pathogenesis and therapeutic challenges","volume":"16","author":"Phoolchund","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.tem.2025.03.006_bb0110","first-page":"691","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.tem.2025.03.006_bb0115","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s13679-024-00597-6","article-title":"Nutritional strategies for battling obesity-linked liver disease: the role of medical nutritional therapy in metabolic dysfunction-associated steatotic liver disease (MASLD) management","volume":"14","author":"Simancas-Racines","year":"2025","journal-title":"Curr. Obes. Rep."},{"key":"10.1016\/j.tem.2025.03.006_bb0120","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3350\/cmh.2024.0564","article-title":"Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis","volume":"31","author":"Rouillard","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0125","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.tem.2025.03.006_bb0130","doi-asserted-by":"crossref","DOI":"10.15420\/ecr.2023.34","article-title":"Treatment options and continuity of care in metabolic-associated fatty liver disease: a multidisciplinary approach","volume":"19","author":"Lara-Romero","year":"2024","journal-title":"Eur. Cardiol."},{"key":"10.1016\/j.tem.2025.03.006_bb0135","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejim.2024.01.005","article-title":"Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease","volume":"122","author":"Armandi","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.tem.2025.03.006_bb0140","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.3748\/wjg.v30.i30.3541","article-title":"Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Soresi","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.tem.2025.03.006_bb0145","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.tem.2022.03.005","article-title":"SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease","volume":"33","author":"Moon","year":"2022","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.tem.2025.03.006_bb0150","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.3390\/ijms23063107","article-title":"SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection?","volume":"23","author":"Androutsakos","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tem.2025.03.006_bb0155","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study","volume":"82","author":"Harrison","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0160","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1111\/apt.17848","article-title":"Role of lifestyle and glucagon-like peptide-1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases","volume":"59","author":"Giannakogeorgou","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.tem.2025.03.006_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.615409","article-title":"Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis","volume":"12","author":"Lian","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.tem.2025.03.006_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2023.102174","article-title":"Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review and meta-analysis","volume":"47","author":"Bandyopadhyay","year":"2023","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.tem.2025.03.006_bb0175","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202004168","article-title":"Mistranslation drives alterations in protein levels and the effects of a synonymous variant at the fibroblast growth factor 21 locus","volume":"8","author":"Bayoumi","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.tem.2025.03.006_bb0180","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/ueg2.12534","article-title":"Fibroblast growth factor 21 is a hepatokine involved in MASLD progression","volume":"12","author":"Gallego-Dur\u00e1n","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.tem.2025.03.006_bb0185","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jhep.2024.04.034","article-title":"FGF21 Agonists: an emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond","volume":"81","author":"Harrison","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0190","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1080\/14656566.2024.2374463","article-title":"Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?","volume":"25","author":"Puengel","year":"2024","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.tem.2025.03.006_bb0195","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3390\/antiox13030329","article-title":"roles of traditional and next-generation probiotics on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a systematic review and network meta-analysis","volume":"13","author":"Zhu, y.","year":"2024","journal-title":"Antioxidants"},{"key":"10.1016\/j.tem.2025.03.006_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2024.108780","article-title":"The effect of probiotic consumption on lipid profile, glycemic index, inflammatory markers, and liver function in NAFLD patients: A systematic review and meta-analysis of randomized controlled trials","volume":"38","author":"Mozaffari","year":"2024","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.tem.2025.03.006_bb0205","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jhep.2023.08.030","article-title":"Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): beyond insulin resistance","volume":"79","author":"Hutchison","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0210","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2025.03.006_bb0215","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S2468-1253(24)00049-9","article-title":"Resmetirom for NASH: balancing promise and prudence","volume":"9","author":"Hepatology","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0220","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.3390\/nu13093067","article-title":"Microbiota\u2019s role in diet-driven alterations in food intake: satiety, energy balance, and reward","volume":"13","author":"Rautmann","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.tem.2025.03.006_bb0225","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/jpm14010061","article-title":"Non-pharmacological approach to diet and exercise in metabolic-associated fatty liver disease: bridging the gap between research and clinical practice","volume":"14","author":"Ali","year":"2024","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.tem.2025.03.006_bb0230","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.tips.2024.05.004","article-title":"Implications of innate immune sexual dimorphism for MASLD pathogenesis and treatment","volume":"45","author":"Booijink","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tem.2025.03.006_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2024.102400","article-title":"Diagnostic performance of sixteen biomarkers for MASLD: A study in a Mexican cohort","volume":"48","author":"Priego-Parra","year":"2024","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.tem.2025.03.006_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2024.1332870","article-title":"Screening for social determinants of health among populations at risk for MASLD: a scoping review","volume":"12","author":"Kim","year":"2024","journal-title":"Front. Public Health"},{"key":"10.1016\/j.tem.2025.03.006_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpsychores.2024.111829","article-title":"Childhood maltreatment and risk of metabolic dysfunction-associated steatotic liver disease \u2013 evidence of sex-specific associations in the general population","volume":"183","author":"Siewert-Markus","year":"2024","journal-title":"J. Psychosom. Res."},{"key":"10.1016\/j.tem.2025.03.006_bb0250","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000324","article-title":"Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States","volume":"7","author":"Ochoa-Allemant","year":"2023","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.tem.2025.03.006_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155937","article-title":"Obesity and MASLD: is weight loss the (only) key to treat metabolic liver disease?","volume":"157","author":"Huttasch","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.tem.2025.03.006_bb0260","article-title":"Clinical utility of genetic variants in PNPLA3 and TM6SF2 to predict liver-related events in metabolic dysfunction-associated steatotic liver disease","volume":"45","author":"Seko","year":"2024","journal-title":"Liver Int."},{"key":"10.1016\/j.tem.2025.03.006_bb0265","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3350\/cmh.2024.0703","article-title":"TM6SF2 and PNPLA3: a potential dynamic duo?","volume":"31","author":"Caddeo","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0270","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/s12876-023-02997-9","article-title":"Sex- and reproductive status-specific relationships between body composition and non-alcoholic fatty liver disease","volume":"23","author":"Cao","year":"2023","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.tem.2025.03.006_bb0275","article-title":"Hepatic estrogen receptor alpha drives masculinization in post-menopausal women with metabolic dysfunction-associated steatotic liver disease","volume":"6","author":"Meda","year":"2024","journal-title":"JHEP Rep."},{"key":"10.1016\/j.tem.2025.03.006_bb0280","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.3390\/ijms20112841","article-title":"NAFLD in some common endocrine diseases: prevalence, pathophysiology, and principles of diagnosis and management","volume":"20","author":"Lonardo","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tem.2025.03.006_bb0285","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2174\/1381612826666200122153055","article-title":"NAFLD at the interface of the mother-infant dyad","volume":"26","author":"Bertrando","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.tem.2025.03.006_bb0290","doi-asserted-by":"crossref","first-page":"16","DOI":"10.20517\/mtod.2023.17","article-title":"Concise review: breastfeeding, lactation, and NAFLD. An updated view of cross-generational disease transmission and prevention","volume":"3","author":"Lonardo","year":"2023","journal-title":"Metab. Target. Organ Damage"},{"key":"10.1016\/j.tem.2025.03.006_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156043","article-title":"Comparative efficacy of THR-\u03b2 agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: a systematic review and network meta-analysis","volume":"161","author":"Lin","year":"2024","journal-title":"metabolism"},{"key":"10.1016\/j.tem.2025.03.006_bb0300","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/j.cgh.2024.05.052","article-title":"Genetics of metabolic dysfunction-associated steatotic liver disease: the state of the art update","volume":"22","author":"Sookoian","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0305","article-title":"Multi-modal analysis of human hepatic stellate cells identifies novel therapeutic targets for metabolic dysfunction-associated steatotic liver disease","author":"Kim","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0310","doi-asserted-by":"crossref","DOI":"10.1038\/s41575-025-01048-w","article-title":"Clusters of metabolic dysfunction-associated steatotic liver disease for precision medicine","author":"Stefan","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0315","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1007\/s00125-021-05625-x","article-title":"A novel diabetes typology: towards precision diabetology from pathogenesis to treatment","volume":"65","author":"Herder","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.tem.2025.03.006_bb0320","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-8587(19)30187-1","article-title":"Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study","volume":"7","author":"Zaharia","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.tem.2025.03.006_bb0325","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tem.2025.03.006_bb0330","article-title":"Targeting PNPLA3 to Treat MASH and MASH related fibrosis and cirrhosis","volume":"45","author":"Lind\u00e9n","year":"2024","journal-title":"Liver Int."},{"key":"10.1016\/j.tem.2025.03.006_bb0335","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jhep.2020.04.003","article-title":"Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort","volume":"73","author":"Anstee","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0340","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1016\/j.cgh.2023.04.024","article-title":"Impact of PNPLA3 rs738409 polymorphism on the development of liver-related events in patients with nonalcoholic fatty liver disease","volume":"21","author":"Rosso","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0345","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1056\/NEJMc2402341","article-title":"Phase 1 trials of PNPLA3 siRNA in I148M homozygous patients with MAFLD","volume":"391","author":"Elisa","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2025.03.006_bb0350","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1038\/ncomms5309","article-title":"TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease","volume":"5","author":"Liu","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tem.2025.03.006_bb0355","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5114\/ceh.2024.136326","article-title":"Association of GCKR and MBOAT7 genetic polymorphisms with non-alcoholic fatty liver disease","volume":"10","author":"Chavan","year":"2024","journal-title":"Clin. Exp. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0360","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/jgh.16521","article-title":"PARVB and HSD17B13 variants are associated with nonalcoholic fatty liver disease in children","volume":"39","author":"Lee","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0365","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1016\/j.cgh.2022.11.002","article-title":"The protection conferred by HSD17B13 rs72613567 on hepatic fibrosis is likely mediated by lowering ballooning and portal inflammation","volume":"21","author":"Vilar-Gomez","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0370","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/apt.18099","article-title":"The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes","volume":"60","author":"Bridi","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.tem.2025.03.006_bb0375","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2024.03.045","article-title":"Genetic risk accentuates dietary effects on hepatic steatosis, inflammation and fibrosis in a population-based cohort","volume":"81","author":"Chen","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0380","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jhep.2020.07.048","article-title":"miR-552-3p modulates transcriptional activities of FXR and LXR to ameliorate hepatic glycolipid metabolism disorder","volume":"74","author":"Fan","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0385","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jhep.2016.12.016","article-title":"MicroRNA-206 prevents hepatosteatosis and hyperglycemia by facilitating insulin signaling and impairing lipogenesis","volume":"66","author":"Wu","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0390","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1096\/fj.201700875R","article-title":"Dual regulation of HMGB1 by combined JNK1\/2\u2013ATF2 axis with miR-200 family in nonalcoholic steatohepatitis in mice","volume":"32","author":"Chen","year":"2018","journal-title":"FASEB J."},{"key":"10.1016\/j.tem.2025.03.006_bb0395","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.3390\/genes12121852","article-title":"Sesn3 inhibited smad3 to relieve its suppression for mir-124, thus regulating pre-adipocyte adipogenesis","volume":"12","author":"Lin","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.tem.2025.03.006_bb0400","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jhep.2012.08.008","article-title":"miR-34a\/SIRT1\/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease","volume":"58","author":"Castro","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0405","first-page":"C588","article-title":"Circulating miRNAs associated with nonalcoholic fatty liver disease","volume":"324","author":"Atic","year":"2023","journal-title":"Am. J. Phys. Cell Phys."},{"key":"10.1016\/j.tem.2025.03.006_bb0410","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jhep.2018.08.008","article-title":"miRNAs in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"69","author":"Liu","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0415","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12902-024-01663-9","article-title":"Sex hormones differently regulate lipid metabolism genes in primary human hepatocytes","volume":"24","author":"Seidemann","year":"2024","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.tem.2025.03.006_bb0420","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2295429","article-title":"Gut microbiome responds to alteration in female sex hormone status and exacerbates metabolic dysfunction","volume":"16","author":"Cross","year":"2024","journal-title":"Gut Microbes"},{"key":"10.1016\/j.tem.2025.03.006_bb0425","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cgh.2020.04.067","article-title":"Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis","volume":"19","author":"Balakrishnan","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0430","first-page":"984","article-title":"Gender differences in the pathogenesis and risk factors of hepatocellular carcinoma","volume":"12","author":"Nevola","year":"2023","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.tem.2025.03.006_bb0435","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1007\/s10620-013-2731-9","article-title":"United States women receive more curative treatment for hepatocellular carcinoma than men","volume":"58","author":"Cauble","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.tem.2025.03.006_bb0440","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.tem.2025.03.006_bb0445","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/hep.510290307","article-title":"Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats","volume":"29","author":"Yasuda","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.tem.2025.03.006_bb0450","article-title":"Non-alcoholic fatty liver disease in women \u2013 current knowledge and emerging concepts","volume":"5","author":"Eng","year":"2023","journal-title":"JHEP Rep."},{"key":"10.1016\/j.tem.2025.03.006_bb0455","doi-asserted-by":"crossref","first-page":"382","DOI":"10.5604\/01.3001.0009.8593","article-title":"Testosterone, sex hormone-binding globulin and nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"16","author":"Jaruvongvanich","year":"2017","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0460","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.cgh.2017.02.036","article-title":"Patient sex, reproductive status, and synthetic hormone use associate with histologic severity of nonalcoholic steatohepatitis","volume":"15","author":"Smith","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0465","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1437046","article-title":"Role of the type 3 cytokines IL-17 and IL-22 in modulating metabolic dysfunction-associated steatotic liver disease","volume":"15","author":"Abdelnabi","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tem.2025.03.006_bb0470","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jhep.2024.06.040","article-title":"Induction of steatosis in primary human hepatocytes recapitulates key pathophysiological aspects of metabolic dysfunction-associated steatotic liver disease","volume":"82","author":"Kwon","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0475","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1038\/s41591-023-02553-8","article-title":"Interaction between estrogen receptor-\u03b1 and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women","volume":"29","author":"Cherubini","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.tem.2025.03.006_bb0480","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000523","article-title":"Sex- and age-associated factors drive the pathophysiology of MASLD","volume":"8","author":"Yadav","year":"2024","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.tem.2025.03.006_bb0485","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.molmed.2024.05.013","article-title":"Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Cherubini","year":"2024","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.tem.2025.03.006_bb0490","article-title":"Factors influencing adherence to lifestyle prescriptions among patients with nonalcoholic fatty liver disease: a qualitative study using the health action process approach framework","volume":"11","author":"Wang","year":"2023","journal-title":"Front. Public Health"},{"key":"10.1016\/j.tem.2025.03.006_bb0495","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0300362","article-title":"Health-related quality of life in non-alcoholic fatty liver disease: A cross-cultural study between Spain and the United Kingdom","volume":"19","author":"Funuyet-Salas","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.tem.2025.03.006_bb0500","doi-asserted-by":"crossref","first-page":"123","DOI":"10.14744\/hf.2023.2023.0034","article-title":"Chronotype preference, sleep quality, and night-eating behaviors in patients with metabolic dysfunction-associated steatotic liver disease: assessing the relationship with disease severity and fibrosis","volume":"4","author":"Sakalli Kani","year":"2023","journal-title":"Hepatol. Forum"},{"key":"10.1016\/j.tem.2025.03.006_bb0505","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.gastrohep.2024.04.001","article-title":"LiverAI: new tool in the landscape for liver health","volume":"47","author":"Marti-Aguado","year":"2024","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0510","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/s12905-023-02544-4","article-title":"The global prevalence of sexual dysfunction in obese and overweight women: a systematic review and meta-analysis","volume":"23","author":"Salari","year":"2023","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.tem.2025.03.006_bb0515","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s12072-024-10663-9","article-title":"Lifestyle intervention for metabolic dysfunction-associated fatty liver disease: a 24-h integrated behavior perspective","volume":"18","author":"Keating","year":"2024","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.tem.2025.03.006_bb0520","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0525","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jhep.2020.04.011","article-title":"Animal models for liver disease - a practical approach for translational research","volume":"73","author":"Nevzorova","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0530","first-page":"559","article-title":"In vitro models for the study of liver biology and diseases: advances and limitations","volume":"15","author":"Kaur","year":"2023","journal-title":"CMGH"},{"key":"10.1016\/j.tem.2025.03.006_bb0535","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jhep.2024.01.029","article-title":"Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice","volume":"80","author":"Zou","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2025.03.006_bb0540","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","article-title":"The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","volume":"14","author":"Eslam","year":"2020","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.tem.2025.03.006_bb0545","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.tem.2025.03.006_bb0550","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.clnu.2023.03.021","article-title":"Practical guideline on obesity care in patients with gastrointestinal and liver diseases - joint ESPEN\/UEG guideline","volume":"42","author":"Bischoff","year":"2023","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.tem.2025.03.006_bb0555","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.cld.2019.09.009","article-title":"Drug-induced liver injury secondary to herbal and dietary supplements","volume":"24","author":"Zheng","year":"2020","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.tem.2025.03.006_bb0560","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M22-1787","article-title":"Effect of calorie-unrestricted low-carbohydrate, high-fat diet versus high-carbohydrate, low-fat diet on type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial","volume":"176","author":"Hansen","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.tem.2025.03.006_bb0565","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s40795-024-00961-8","article-title":"Which dietary patterns fend off nonalcoholic fatty liver disease? A systematic review of observational and interventional studies","volume":"10","author":"Bakhshimoghaddam","year":"2024","journal-title":"BMC Nutr."},{"key":"10.1016\/j.tem.2025.03.006_bb0570","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.3390\/nu16132027","article-title":"A healthful plant-based diet as an alternative dietary approach in the management of metabolic dysfunction-associated steatotic liver disease","volume":"16","author":"Castelnuovo","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.tem.2025.03.006_bb0575","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1095753","article-title":"Effect of dual glucose-dependent insulinotropic peptide\/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity","volume":"14","author":"Zaffina","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.tem.2025.03.006_bb0580","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2024.1355732","article-title":"Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies","volume":"11","author":"Al Hashmi","year":"2024","journal-title":"Front. Nutr."},{"key":"10.1016\/j.tem.2025.03.006_bb0585","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/cpt.3278","article-title":"Efficacy and safety of fibroblast growth factor-21 analogs for the treatment of metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis","volume":"116","author":"Jeong","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.tem.2025.03.006_bb0590","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.clnesp.2021.06.015","article-title":"Effect of omega-3 supplementation on fatty liver and visceral adiposity indices in diabetic patients with non-alcoholic fatty liver disease: a randomized controlled trial","volume":"44","author":"Sangouni","year":"2021","journal-title":"Clin. Nutr. ESPEN"}],"container-title":["Trends in Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276025000529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276025000529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:39:40Z","timestamp":1762353580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043276025000529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":118,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1043276025000529"],"URL":"https:\/\/doi.org\/10.1016\/j.tem.2025.03.006","relation":{},"ISSN":["1043-2760"],"issn-type":[{"value":"1043-2760","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease","name":"articletitle","label":"Article Title"},{"value":"Trends in Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tem.2025.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}